Breaking Finance News

BNP PARIBAS disclosed Fresenius (ETR:FRE), boosting its stock price target to 78.00EUR earlier today

Indicating a possible upside of 0.13%, BNP PARIBAS bumped the target stock price of Fresenius (ETR:FRE) to 78EUR.

Previously on Monday September 12 2016, BNP PARIBAS released a statement for Fresenius(ETR:FRE) raised the target price from 0.00EUR to 78.00EUR that indicated a possible upside of 0.13%.

Showing a price of 69.12EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. The last stock price is up 0.00% from the 200-day moving average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. The company has registered a 50-day average of 0.00EUR and 200-day moving average of 0.00EUR. 0 shares of the stock were exchanged, from ann avg. volume of 0

Recent Performance Graphic:

Fresenius (ETR:FRE)

Fresenius has a one-year low of 0.00EUR and a one-year high of 0.00EUR. FRE’s market cap is presently 0.0 EUR.

Brief Synopsis About Fresenius (ETR:FRE)

Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, and clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.